D.R Congo Approves ‘MANACOVID’ as Anti-Covid Drug

A driver’s temperature is measured at a border between Abuja and the Nasarawa State on March 30, 2020, as he leaves to neighbouring states after Nigeria’s President Muhammadu Buhari called for a lockdown to limit the spread of the COVID-19 coronavirus. – Over 20 million Nigerians on Monday scrambled to prepare for lockdown in sub-Saharan Africa’s biggest city Lagos and the capital Abuja, as the continent struggled to curb the spread of the COVID-19 coronavirus. President Muhammadu Buhari has ordered a two-week “cessation of all movements” in the key cities from 2200 GMT in a bid to ward off an explosion of cases in Africa’s most populous country. (Photo by Kola SULAIMON / AFP)

The Luozi pharmaceutical research centre (CRPL) in the Democratic Republic of Congo, has approved the “MANACOVID” drug to treat the coronavirus infections in Democratic Republic of Congo.

According to a statement, the results were observed by three teams of doctors on a total of 300 cases that tested positive to COVID-19, all these cases proved negative with the disappearance of symptoms and a good tolerance, within five days of treatment.

“MANACOVID”, a product based on local medicinal plants, was approved on 24 November 2020 and issued a certificate of invention as evidence.

The drug was discovered in March 2020 by Congolese chemist-doctor, Etienne Flaubert Batangu Mpesa, following his work with a team of pharmacist researchers, the statement said.

Your Friends Also Read:  Bitter sweets: Madagascar minister fired over candy plan

MANACOVID is one of three projects selected and recommended by the Ministry of Scientific Research and Technologic innovation since 14 April 2020 for clinical tests.

Before its approval, all the processes were respected, particularly the approval of the MANACOVID protocol by the National Health Ethics Committee (CNES).

The clinical tests were carried out from June to October 2020 through three independent teams of Congolese investigative doctors registered with the DRC Doctors Order under the coordination of a principal-investigator.

Pharmacist Etienne Flaubert Batangu Mpesa graduated at Lovanium University since 1971, now University of Kinshasa (UNIKIN). He became a teacher of Pharmaceutical sciences at Montreal, Quebec/Canada University in 1980.

Your Friends Also Read:  Algeria insists on hydroxychloroquine for Covid-19 treatment

Mpesa, now chairman of the board of directors of CRPL, is the inventor of the products Manadiar (against amebic diarrhoea) and Manalaria (anti-malaria).

All rights reserved. This material, and other digital content on this website, may not be reproduced, published, broadcast, rewritten or redistributed in whole or in part without prior express written permission from News Central TV.

Contact: digital@newscentral.ng


Leave a Reply

Previous Article

East Africa Loses Billions in Tax Exemptions and Remissions

Next Article

France Awaits Verdict in Charlie Hebdo Trial

Related Posts
Powered by Live Score & Live Score App